The US Food and Drug Administration (FDA) has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for CRESEMBA (isavuconazonium sulfate) as a treatment for fungal infections, including invasive aspergillosis (IA) or invasive mucormycosis (IM) in paediatric patients.

CRESEMBA is a prodrug of the azole antifungal, isavuconazole.

The regulator has set 9 December 2023 as the Prescription Drug User Fee Act goal date for the review of Astellas’ sNDA.

The sNDA is based on results from a Phase II open-label, multicentre, non-comparative study that evaluated the tolerability, safety, efficacy and pharmacokinetics of CRESEMBA.

Astellas’ study enrolled 31 participants aged from one to 17 years diagnosed with IA or IM.

Participants received a loading dose of CRESEMBA intravenously or at the investigator’s discretion, and an oral dose every eight hours on days one and two.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

They were then followed while receiving a once-daily maintenance dose.

Astellas US Medical Specialties business unit head and senior vice-president Lynn Fenicchia stated: “Since its approval over eight years ago, CRESEMBA has been helping adult patients and their physicians fight certain life-threatening fungal infections when they are often critically ill with other diseases.

“This sNDA acceptance by the FDA brings Astellas one step closer to helping paediatric patients by potentially having a new treatment option available for IA and IM for a younger patient population if approved.”

The most frequently reported adverse reactions among CRESEMBA-treated patients included nausea (26%), vomiting (25%), diarrhoea (22%), headache (17%) and elevated liver chemistry tests (16%).

The adverse reactions which most often led to permanent discontinuation of therapy during the clinical trials were confusional state (0.7%), acute renal failure (0.7%), increased blood bilirubin (0.5%), convulsion (0.5%), dyspnea (0.5%), epilepsy (0.5%), respiratory failure (0.5%), and vomiting (0.5%).

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now